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Background
High-sensitivity (hs) cardiac troponin is a valuable
biomarker of myocardial injury and frequently elevated
in patients with hypertrophic cardiomyopathy (HCM).
Using cardiovascular magnetic resonance (CMR) the
HCM phenotype can be characterized in great detail
with fibrosis as a key finding with prognostic impact.
Therefore, our aim was to investigate whether elevated
troponin levels in patients with clinical HCM were asso-
ciated with LV hypertrophy and fibrosis as assessed with
CMR.
Methods
In 62 clinical HCM patients (58% males, mean age 51 ±
15 years) hs-troponin T was determined with a high-
sensitivity assay (Roche Diagnostics). The lower detection
limit is 0.003 pg/l and an elevated hs-troponin is defined
as a concentration ≥ the 99th percentile reference limit
(≥ 0.014 pg/l). CMR with late gadolinium enhancement
(LGE) was performed (Philips Achieva 1.5T) to assess LV
mass indexed to body surface area, maximal wall thick-
ness (MWT) and fibrosis. LV mass, MWT and the pre-
sence and extent of LGE were assessed (QMass 7.0,
Medis) and compared between HCM patients with and
without an elevated hs-troponin using Mann Whitney U
or Fisher exact testing.
Results
Hs-troponin was detectable in 46 HCM patients (74%),
of whom 16 patients had an elevated hs-troponin level.
The median LV mass and MWT were higher in HCM
patients with an elevated hs-troponin (p<0.001). The dif-
ference in the presence of fibrosis was almost statisti-
cally significant between groups. Notably, if present, the
extent of fibrosis was higher in patients with an elevated
hs-troponin (p= 0.04) (Table 1).
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Table 1
Total N = 62 Troponin not elevated N = 46 Troponin elevated N = 16 P
LV mass indexed to BSA (g/m2) (median; IQR) 65; 52-91 61; 51-81 101; 67-130 0.001
Maximal LV wall thickness (mm) (median; IQR) 18; 13-21 16; 13-20 21; 18-24 0.002
Fibrosis present n (%) 31 (50%) 20 (44%) 11 (69%) 0.08
Fibrosis extent in LGE positive patients (%) (median; IQR) 10; 5-14 7; 3-12 14; 9-19 0.04
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Conclusions
Elevated troponin levels assessed with a high-sensitivity
assay are common in HCM patients and associated with
specific features of HCM such as hypertrophy and maxi-
mal wall thickness. Our findings are indicative of troponin
as a potential surrogate marker of myocardial injury in the
form of fibrosis. Future studies will have to address this
issue more elaborately especially with regard to the poten-
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